Teva launches generic Lamictal XR in new strength

NORTH WALES, Penn. — Teva Pharmaceuticals on Wednesday announced the launch of its generic of Lamictal XR (lamotrigine) extended-release tablets in 250-mg dosage strength. 

 

The drug is indicated as an adjunctive therapy for patients older than 13 years of age with tonic-clonic seizure or partial-onset seizures with or without secondary generalization, and as monotherapy in patients older than 13 with partial onset seizures receiving treatment with a single AED. 

 

Teva has previously launched the drug in 25-, 50-, 100-, 200- and 300-mg dosage strengths.